Vertex's cystic fibrosis drug approved for another 150 U.S. patients

Kalydeco, which was the first drug to treat the underlying cause of cystic fibrosis when it was approved in the U.S. in 2012, is now approved for patients with other gene mutations. The inherited chronic disease is caused by gene mutations that make the body produce unusually thick mucus that affect lung function and the digestive system. It affects about 70,000 people around the world, 30,000 of which are in the U.S. The drug is now sold in the U.S. and Europe for patients 6 and older who have… Reported by bizjournals 2 hours ago.